sotio_BC.png
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
June 04, 2021 08:10 ET | Sotio
PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its...
sotio_BC.png
SOTIO to Present Biomarker Data from its SOV01 – DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting
May 11, 2021 08:41 ET | Sotio
PRAGUE, Czech Republic, May 11, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO...
sotio_BC.png
SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies
April 12, 2021 09:00 ET | Sotio
Results from preclinical, proof-of-concept studies were presented at the 2021 AACR Annual MeetingResults demonstrate strong potential of SOT102 to eliminate tumor cells in a target-specific...
sotio_BC.png
SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting
April 06, 2021 09:00 ET | Sotio
PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021...
sotio_BC.png
SOTIO Presents Interim Data from its Phase 1/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020
November 11, 2020 09:00 ET | Sotio
Late breaking poster demonstrates SO-C101 was well tolerated to date with no dose-limiting toxicitiesConfirmed partial response was observed after SO-C101 monotherapy in a patient with skin squamous...
sotio_BC.png
SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
November 04, 2020 09:00 ET | Sotio
SOTIO will present three posters, including a late breaking poster on the clinical data from the ongoing Phase 1 study of IL-15 superagonist SO-C101 for the treatment of advanced solid tumors PRAGUE,...
sotio_BC.png
SOTIO to Present at BIO-Europe Digital 2020
October 26, 2020 08:00 ET | Sotio
PRAGUE, Czech Republic, Oct. 26, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is...
sotio_BC.png
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics
August 31, 2020 07:30 ET | Sotio
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, MassachusettsUnum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all...
sotio_BC.png
SOTIO to Present at the LifeSci Partners Summer Symposium
July 30, 2020 08:00 ET | Sotio
PRAGUE, Czech Republic, July 30, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that Radek Špíšek, chief executive officer of SOTIO,...
sotio_BC.png
SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors
July 14, 2020 09:00 ET | Sotio
PRAGUE, Czech Republic, July 14, 2020 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the...